Open AccessNaringenin inhibits migration of lung cancer cells via the inhibition of matrix metalloproteinases-2 and −9
Author(s) -
HuaiLu Chang,
YuhMing Chang,
ShihChan Lai,
Kemin Chen,
KuanChu Wang,
TsuTing Chiu,
FuHsin Chang,
LiSung Hsu
Publication year - 2016
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2016.3994
Subject(s) - matrix metalloproteinase , oncogene , naringenin , molecular medicine , cell cycle , cancer research , apoptosis , cancer , lung cancer , chemistry , biology , medicine , biochemistry , flavonoid , antioxidant
Lung cancer is among the most common causes of cancer-related mortality. It has a high mortality rate and resistance to chemotherapy due to its high metastatic potential. Naringenin, a bioactive compound identified in several fruits, displays anti-inflammatory and antitumor effects. Furthermore, naringenin mitigates the migration of several human cancer cell types. However, the effects of naringenin on lung cancer remain unclear. The current study investigated the mechanisms of naringenin on the migration of lung cancer A549 cells. The results indicate that significant alteration in A549 cell proliferation was observed in response to naringenin (0-300 µM) treatment for 24 and 48 h. Furthermore, a dose-dependent migration inhibition of A549 in the presence of naringenin was observed by healing and transwell migration assays. In addition, a zymography assay revealed that naringenin exhibited a concentration-dependent inhibition of matrix metalloproteinase (MMP)-2 and -9 activities. Furthermore, naringenin also inhibited the activities of AKT in a dose-dependent manner. These observations indicated that naringenin inhibited the migration of lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities.